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Abstract
Background: The ‘exposome’ represents the accumulation of all environmental exposures across a lifetime. Top-
down strategies are required to assess something this comprehensive, and could transform our understanding of
how environmental factors affect human health. Metabolic profiling (metabonomics/metabolomics) defines an
individual’s metabolic phenotype, which is influenced by genotype, diet, lifestyle, health and xenobiotic exposure,
and could also reveal intermediate biomarkers for disease risk that reflect adaptive response to exposure. We
investigated changes in metabolism in volunteers living near a point source of environmental pollution: a closed
zinc smelter with associated elevated levels of environmental cadmium.
Methods: High-resolution 1H NMR spectroscopy (metabonomics) was used to acquire urinary metabolic profiles
from 178 human volunteers. The spectral data were subjected to multivariate and univariate analysis to identify
metabolites that were correlated with lifestyle or biological factors. Urinary levels of 8-oxo-deoxyguanosine were
also measured, using mass spectrometry, as a marker of systemic oxidative stress.
Results: Six urinary metabolites, either associated with mitochondrial metabolism (citrate, 3-hydroxyisovalerate, 4-
deoxy-erythronic acid) or one-carbon metabolism (dimethylglycine, creatinine, creatine), were associated with
cadmium exposure. In particular, citrate levels retained a significant correlation to urinary cadmium and smoking
status after controlling for age and sex. Oxidative stress (as determined by urinary 8-oxo-deoxyguanosine levels)
was elevated in individuals with high cadmium exposure, supporting the hypothesis that heavy metal
accumulation was causing mitochondrial dysfunction.
Conclusions: This study shows evidence that an NMR-based metabolic profiling study in an uncontrolled human
population is capable of identifying intermediate biomarkers of response to toxicants at true environmental
concentrations, paving the way for exposome research.
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Background
From the point of conception and throughout life,
humans experience a broad range of physical, chemical
and biological exposures. The health effects of such expo-
sures will depend not only on dose but also on their
interaction with each other and with the characteristics
of the individual, such as age, sex and genotype. Hence, it
is a persistent and significant challenge to understand
how specific environmental factors produce effects on
human health. Biomarkers already play an important role
in characterizing both dose and effect; however, their full
potential remains to be explored. Molecular profiling
technologies (’-omics’) have been suggested to be an
important route to the discovery of novel biomarkers to
improve exposure assessment in man [1]. Such techni-
ques can also report on the biological consequences of
exposure by identifying intermediate biomarkers that
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both correlate with exposure and predict health end-
points, termed a ‘meet-in-the-middle’ approach [2,3].
Such markers would help to define the mechanism of
toxicity and the etiology of disease in the human popula-
tion and ultimately could inform follow-up surveillance
for communities impacted by environmental pollution. It
has been proposed that by combining a wide range of
molecular profile data, including parallel assays of mole-
cular adducts, metals and other exogenous species, we
have the potential to define the molecular imprint of the
totality of environmental exposures in an individual’s life-
time, the ‘exposome’[4,5].
Metabolic profiling allows the study of an individual’s
metabolic phenotype [6,7] and represents a systematic and
efficient route to intermediate biomarkers. It can detect
and classify the consequences of toxicant exposure in vivo
[8,9] and the approach readily translates to molecular epi-
demiology [10]. Here we use an NMR-based metabolic
profiling approach to investigate changes in human sys-
temic metabolism from a sample of the population living
near a point source of environmental pollution. The site
(Avonmouth, UK) was home to one of the world’s largest
smelters and large amounts of cadmium (Cd) and other
potentially toxic elements were released into the local
environment until its closure in early 2003 resulting in the
presence of elevated concentrations of metals in air, soil
and house dust in the area [11].
Cd is a toxic heavy metal of occupational and environ-
mental concern due to its widespread contamination of
sites worldwide [12,13] and long biological half-life (10
to 30 years) [14]. Cd exposure is associated with a host
of adverse effects [15], including osteoporosis, pulmon-
ary dysfunction, hypertension and nephropathy. The
kidney accumulates Cd and is the critical organ, particu-
larly at environmental levels of exposure, with tubular
proteinuria being an early effect of Cd exposure [16].
This proteinuria is usually detected as an increased
excretion of low-molecular weight urinary proteins, such
as N-acetyl-b-D-glucosaminidase (NAG). There is some
evidence to suggest that, following high and/or pro-
longed exposure, these pre-clinical changes may pro-
gress to renal impairment with a decreased glomerular
filtration rate [17-19], and eventually to renal failure
[20].
A further concern is cancer risk; Cd is a multi-site
carcinogen in both rodents [21] and humans [22] and as
such has been classified as a human carcinogen by the
International Agency for Research on Cancer [23] and
the National Toxicology Program [24]. The mechanism
of Cd carcinogenesis is thought to be multi-factorial but
is as yet poorly understood. Cd has been shown to pos-
sess estrogenic activity [25-27], inhibit mismatch repair
[28], alter DNA methylation [29,30] and increase reac-
tive oxygen species (ROS) production [31].
The diet is the major source of Cd exposure in the
general non-smoking population with around 5% to 10%
[32] absorption from the gastrointestinal tract. However,
among smokers tobacco is also a significant source of
exposure owing to the high rate of absorption from the
lungs (10 to 50%) [32]. The low excretion rate of Cd
and the resulting long biological half life means that Cd
body burden increases slowly with age and appears to
accumulate at a higher rate in women compared to
men. Urinary-Cd (U-Cd) concentration is mainly influ-
enced by the total body burden and is, hence, a marker
for long term exposure, but can also increase as kidney
damage occurs [14].
It has been well documented that 1H NMR-based
metabolic profiling (metabonomics/metabolomics) can
detect Cd-induced perturbations of metabolism in ani-
mal models [33-35] with renal damage and biochemical
changes at concentrations that were considered rela-
tively safe in humans by the World Health Organisation
[36]. However, there have not been any comparable
investigations in human populations. In the present
study, we aim to establish that NMR-based metabolic
profiling could be used in molecular epidemiology to
define the metabolic signatures of exposure to toxicants
in the human population and link these to mechanisms
of toxicity. We correlated urinary metabolic profiles of
individuals living near the Avonmouth site with environ-
mental toxicants (U-Cd) and corrected for confounding
lifestyle and biological factors, such as age, sex and
smoking status (Figure 1).
Methods
Sample collection and epidemiology data
One hundred and eighty adult participants were recruited
to the current study as described in Thomas et al. (2009)
[37], and 178 samples in total were analyzed by 1H NMR
spectroscopy. Briefly, each individual was asked to provide
one spot morning urine sample; each sample was frozen
on the day of collection. Each volunteer completed a life-
style questionnaire that provided information on a number
of parameters including smoking status (current, past,
never), age and sex. Data were anonymized for the present
study. U-Cd and U-NAG were previously determined [37]
and were both log-normally distributed. Ethical approval
for the study was granted by Bristol (UK) South and
Central Ethics Committee and all participants provided
their written informed consent before data collection.
NMR data acquisition
Samples were thawed on ice and prepared in a single
batch. For each sample, an aliquot (0.4 mL) was mixed
with buffer (0.2 mL, 0.2 M sodium phosphate, pH 7.4)
containing 2H2O (20% v/v) and sodium 3-trimethylsilyl-1-
[2, 2, 3, 3,-2H4] propionate (TSP, 0.3 mM) and centrifuged
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(16,000 g, ten minutes) to remove suspended particulate
matter.
High-resolution 1H NMR spectroscopy experiments
were conducted using a Bruker AVANCE 600 spectro-
meter (Bruker Biospin, Rheinstetten, Germany) fitted
with a flow-injection mode probehead (5 mm FI TXB
1H-13C/15N-2H Z-GRD H8432/K0201 Z8432/0201, Bru-
ker) at a field strength of 14.1 T (600.13 MHz 1H fre-
quency). The probe temperature was set to 300 K.
Samples were delivered to the probehead in 96-well
plates using an automated flow injection system (Bru-
ker). Following introduction to the probe, samples were
left to equilibrate (three minutes) prior to gradient
shimming using the 1H channel to ensure good mag-
netic field homogeneity. All liquid sample handling,
automation and acquisition were controlled using
XWIN-NMR 3.1 software (Bruker) running on a UNIX
workstation (Silicon Graphics, USA).
One-dimensional NMR spectra were acquired using a
standard pulse sequence using excitation sculpting with
gradients to suppress the water resonance [38]. Follow-
ing eight dummy scans, each spectrum was acquired
into 64 k datapoints over a spectral width of 20 ppm as
the sum of 64 transients. The acquisition time was 2.73
seconds, giving a native free induction decay (FID) reso-
lution of 0.183 Hz. The relaxation delay was set at two
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Figure 1 Metabolic profiling in molecular epidemiology: a methodology to identify intermediate biomarkers of response to
environmental toxicants. A) Map of United Kingdom showing Bristol region. Reproduced from Ordnance Survey map data by permission of
the Ordnance Survey © Crown copyright 2010. B) Air Cd concentration around the Avonmouth zinc smelter site (data from Thomas et al. (2009)
[37]). Contours represent modeled air Cd concentration (ng/m3). Dotted line represents boundary of Bristol North PCT from where volunteers
were recruited. C) Partial 1H NMR one dimensional spectrum with key metabolites annotated. 3-HV, 3-hydroxyisovalerate; DMG, dimethylglycine.
D) Outline of the metabolic profiling and statistical methods used to define associations between the metabolome and environmental toxicants.
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seconds. The total acquisition time was approximately
six minutes per sample. An apodization function equiva-
lent to a line-broadening of 0.3 Hz was applied to each
FID prior to Fourier transformation. Assignment of
peaks to specific metabolites was based on the addition
of known standards to the biological samples, together
with published literature [39], on-line metabolomics
databases and statistical total correlation spectroscopy
(STOCSY) [40]. Additional NMR spectroscopy experi-
ments were conducted to assign a doublet at a chemical
shift of δ 1.11. A one-dimensional 1H selective TOCSY
experiment (See additional file 1, Figure S1) observed
three related 1H resonances in the same molecule.
Further two-dimensional experiments [See additional
file 1, Figure S2] allowed the full 1H and 13C characteri-
zation [See additional file 1, Table S1] of the two dia-
stereoisomers of 2,3-dihydroxybutanoic acid [See
additional file 1, Figure S3]: 4-deoxy-erythronic acid and
4-deoxy-threonic acid, both of which have previously
been identified in human urine [41].
NMR data processing and statistical analysis
Data were imported and manipulated in Matlab (Math-
works, Natick, MA, USA) using in-house code for auto-
matic phasing, baseline correction, and referencing
chemical shifts to the TSP resonance at δ 0. To account for
variance in dilution of the urine samples each spectrum
was subsequently normalized by the median-fold change to
a reference spectrum generated by calculation of the med-
ian of all spectra at each spectral point [42]. The spectra
were analyzed at two resolutions: (1) reduced resolution of
0.01 ppm width (1,127 data points), for partial least squares
(PLS) regression analysis; and (2) high resolution (32,697
data points), for covariance/correlation analysis.
For multivariate analysis the reduced resolution data
were exported to SIMCA-P+ (Umetrics) with the TSP (δ <
0.15) and residual water (δ 4.675 to 4.895) resonances
removed. PLS regression analysis was applied to these data
to model optimally the association between the metabolic
profile and the lifestyle and biological factors (U-Cd, age,
sex, U-NAG and smoking status) and to identify individual
metabolites significantly contributing to any associations
observed. Permutation analysis was carried out for each
PLS model to test for validity using 1,000 permutations
per test [See additional file 1, Figure S4].
Additionally, we used a variable-wise covariance and
correlation based analysis of the high resolution data to
assist in the identification of individual metabolites asso-
ciated with lifestyle/biological factors. The results were
visualized by color-scale projection onto the plots to indi-
cate the correlation of metabolites with the individual fac-
tors, with red indicating a high correlation and dark blue
no correlation. The direction and magnitude of the signals
represent the co-variation of the metabolites with the spe-
cific lifestyle factor.
We measured the area under selected spectral peaks for
six specific metabolites (3-hydroxyisovalerate (3-HV),
dimethylglycine (DMG), citrate, 4-deoxy-erythronic acid
(4-DEA), creatinine and creatine) identified from the
above analyses. These data were then analyzed by multiple
linear regression (MLR) using SPSS (v19, IBM, Armonk,
NY, USA) controlling for major confounding factors (age,
sex and smoking status). We developed three separate
MLR models for citrate. Model 1 excluded individuals
who did not answer the question regarding smoking status
(n = 3); model 2 additionally excluded all individuals
classed as current smokers (n = 32); and model 3 addition-
ally excluded current (n = 32) and past smokers (n = 35).
Additionally, we used non-parametric tests (Kruskal-
Wallis/Mann-Whitney or Spearman’s r) to test for a sig-
nificant (P < 0.05) difference or trend, respectively, in the
concentration of citrate between the three classes of smo-
ker (current-, past-, and never smoked). A normal distri-
bution of values in each group in the dataset was observed
(P < 0.05, Shapiro-Wilk test).
Quantitation of the urinary biomarker 8-oxo-
deoxyguanosine (8-oxodG)
Urinary-8-oxodG (U-8-oxodG) was quantified in samples
from the upper and lower 15th percentile according to U-
Cd concentration, as described previously [43]. The U-8-
oxodG concentrations were normalized to the creatinine
concentration (taken from [37]) and a non-parametric
Mann-Whitney test used to test for a significant (P < 0.05)
difference between the groups. A non-normal distribution
of values in the upper 15th percentile group was observed
(P < 0.05, Shapiro-Wilk test).
Results
Effects of Cd exposure on endogenous metabolism
Our first objective was to determine if there were any
associations between the global metabolic profile and U-
Cd. Initial inspection of the spectral data indicated that
a substantial number of individuals had detectable levels
of analgesics (that is, paracetamol and ibuprofen) and/or
ethanol detectable in their samples (51/178, approxi-
mately 29%, see additional file 1, Table S2). In order to
avoid subsequent models being negatively affected by
the global diuretic or pharmacological effects of these
compounds on the spectra, these individuals were
excluded from initial pattern recognition analyses. From
the reduced resolution data-set (see Methods), PLS
regression could predict U-Cd based on the metabolic
profile data (Q2 = 0.237, P < 0.01, Table 1). Inspection
of model regression weights and bivariate analyses at
both low and high resolution (Figure 2A) identified a
Ellis et al. BMC Medicine 2012, 10:61
http://www.biomedcentral.com/1741-7015/10/61
Page 4 of 10
number of urinary metabolites responsible for this asso-
ciation, namely: citrate, 3-HV, DMG, creatinine, creatine
and 4-DEA. DMG, 3-HV, creatinine and 4-DEA were
negatively correlated to U-Cd concentration and citrate
was positively correlated.
Since smoking is a major source of cadmium exposure
we excluded smokers from PLS modelling to test if
the link between metabolite profiles and U-Cd was
independent of smoking status. PLS models with signifi-
cant prediction of U-Cd could be generated either with
current smokers excluded (Q2 = 0.330, P < 0.001, Table
1) or with both current smokers and past smokers
excluded (Q2 = 0.142, P < 0.001, Table 1), suggesting
that exposure to Cd from environmental and dietary
sources alone may be sufficient to produce detectable
metabolic effects.
Table 1 Statistics of multivariate analysis models demonstrating an association between 1H NMR spectroscopic data
and several biological and lifestyle factors.
Model Description Y variable Number of LVs R2X Q2Y Significance
(P value)
A. PLS ln(U-Cd) 3 0.251 0.237 < 0.01
B. PLS
(current smokers excluded)
ln(U-Cd) 5 0.308 0.330 < 0.001
C. PLS
(past and current smokers excluded)
ln(U-Cd) 1 0.0729 0.142 < 0.001
D. PLS sex 3 0.241 0.104 > 0.05
E. PLS age 2 0.216 0.224 < 0.001
F. PLS ln(U-NAG) 1 0.054 0.162 < 0.001
G. PLS-DA Smoking historya 2 0.194 0.185 < 0.01
aSmoking history was defined as either 1 = never smoked and past smoker (n = 106) or 2 = current smoker (n = 20), one individual did not complete the
lifestyle questionnaire. Spectra that exhibited signs of bacterial contamination, analgesics or ethanol were excluded from these analyses. All variables were mean-
centred and scaled to unit variance. NMR data were reduced to 1,127 data points of δ 0.01 resolution. Sample numbers for PLS models: A, D, E and F: n = 127. B:
n = 106. C: n = 79. PLS-DA (model G) n = 126. Number of latent variables in a model were auto-fitted in SIMCA-P+. All models were assessed for validity by Y
variable permutation analysis (1,000 permutations, see additional file 1 Figure S4). Scores scatter plots for each multivariate model can also be found in
additional file 1 (Figure S5). ln(U-Cd), natural logarithm of urinary cadmium; ln(U-NAG), natural logarithm of urinary-N-acetyl-b-D-glucosaminidase; LV, latent
variable; n, sample number; PLS, partial least squares; PLS-DA, partial least squares - discriminant analysis. R2X is the proportion of variance in the X matrix (i.e.
spectral NMR data) described by the PLS model. Q2Y is the ability of the PLS model to predict the Y-score (ln(U-Cd), sex, age, ln(U-NAG) or smoking status) of a
novel sample or the “cross-validated goodness-of-fit”.
Figure 2 Covariance and correlation between 1H NMR one dimensional urine spectra, and population characteristics. The color code
(R2) corresponds to the correlation coefficients of the variables with each of the characteristics: A, ln(U-Cd); B, age; C, sex; D, ln(U-NAG); and E,
smoking status. N = 127. a - The direction and magnitude of the signals relate to the covariation of the metabolites with sex in the model, that
is, female (positive) and male (negative). b - Smoking status was classified into two classes. 1 = never smoked (negative), 2 = current smoker
(positive). 3-HV, 3-hydroxyisovalerate; DMG, dimethylglycine; 4-DEA, 4-deoxyerythronic acid. Spectra that exhibited signs of bacterial
contamination, analgesics or ethanol were excluded from these analyses [See additional file 1 Table S2].
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Association between other factors and endogenous
metabolism
It has already been shown in this population that U-Cd is
significantly associated with age, sex, U-NAG and smoking
status [37]. In order to obtain a better understanding of
possible causal links and the specificity of the responses to
Cd we conducted further pattern recognition analyses to
attempt to derive models for these potentially confounding
factors. We could predict a statistically significant degree
of variation by PLS regression in each of: age (Q2 = 0.224,
P < 0.001), smoking status (Q2 = 0.185, P < 0.01) and U-
NAG levels (Q2 = 0.162, P < 0.001) from the urinary NMR
data (Table 1). Inspection of regression weights for each of
these models indicated that several metabolites correlated
with U-Cd levels (that is, 3-HV, DMG, 4-DEA and creati-
nine) were also associated with these other physiological
and lifestyle factors. Further specific metabolite correlates
were defined, including cotinine to smoking status and
creatine to sex (Figures 2B-2E).
Regression analysis of individual urinary metabolite levels
Next we measured the area under selected spectral peaks
(the integral) for the six metabolites (3-HV, DMG, citrate,
creatinine, creatine and 4-DEA) identified by pattern recog-
nition analysis as associated with U-Cd, and analyzed these
in more detail by MLR. Samples previously excluded (n =
51) from pattern recognition analysis due to the presence
of ethanol or analgesics were evenly distributed across age,
smoking status, gender and U-Cd, reducing the likelihood
that including these samples would confound the analysis
[See additional file 1, Table S2]. Hence we felt it was justi-
fied to include these data for individual metabolite analyses
to increase power wherever the relevant resonances could
be integrated without interference. The integral of each
metabolite was regressed as a function of U-Cd, age, sex
and smoking status (Table 2). There was a significant asso-
ciation between citrate levels and both U-Cd (beta = 0.194,
P < 0.05) and smoking status (beta = -0.298, P < 0.001) con-
trolling for age and sex. Interestingly, citrate was positively
correlated to U-Cd but negatively correlated to smoking
status. This suggests that exposure to cigarette smoke via
inhalation, although known to significantly increase Cd
body burden, may have a different effect than Cd exposure
alone via ingestion and/or inhalation (as assessed by U-Cd).
Other metabolites showed significant associations to the
potential confounding factors but not to U-Cd. 3-HV was
negatively associated with age (beta = -0.326, P < 0.001)
and sex (beta = -0.233, P < 0.01), and 4-DEA to age only
(beta = -0.370, P < 0.001). Creatinine was negatively asso-
ciated with age (beta = -0.427, P < 0.001) and sex (beta =
-0.395, P < 0.001). Creatine was positively associated with
sex only (beta = 0.321, P < 0.001). Again, we excluded smo-
kers from the regression models, in order to establish if
environmental exposure alone could account for the link
between Cd body burden and perturbed endogenous meta-
bolism. Citrate levels remained significantly associated with
U-Cd while controlling for all other factors with either cur-
rent smokers, or current and past smokers, removed from
the regression model (Table 2; models citrate(2) and citrate
(3) respectively).
Interestingly, there was a significant association
between smoking status and citrate, even when current
smokers were removed, suggesting that there was a meta-
bolic difference between those individuals who had never
smoked and those who had previously smoked. Normal-
ized citrate levels were significantly different between
groups (P < 0.05, Kruskal-Wallis test), specifically
between current smokers and those who had never
Table 2 Correlation coefficients (standardized beta values) derived from multiple linear regression of key metabolite
to lifestyle factors.
Metabolite Chemical shift Sample number Correlation to Y variable
(ppm) number (U-Cd) age sex smoking statusa
3-HV 1.276 to 1.269 160 -0.056 -0.326*** -0.233** -0.023
DMG 2.936 to 2.920 176 -0.127 -0.122 -0.168 -0.052
citrate (1) 2.515 to 2.590 175 0.194* -0.078 0.126 -0.298***
citrate (2) 2.515 to 2.590 143 0.228* -0.060 0.157 -0.203*
citrate (3) 2.515 to 2.590 108 0.251* -0.046 0.121 n/a
Creatinine 4.073 to 4.040 178 -0.010 -0.427*** -0.395*** 0.015
Creatine 3.940 to 3.930 178 -0.006 0.088 0.321*** 0.150
4-DEA 1.118 to 1.108 152 -0.042 -0.370*** -0.076 0.039
aSmoking status was classified into three classes. 1 = never smoked, 2 = past smoker and 3 = current smoker. Specific exclusions were made for each metabolite
identified where coinciding interferences made the relevant resonance unsuitable for integration. All six metabolites were correlated to at least one of the
epidemiological factors in either the PLS/PLS-DA regression analysis or the covariance/correlation models. Asterisks denote statistical significance (ANOVA with
Bonferroni post-hoc correction): * P < 0.05, ** P < 0.01, *** P < 0.001. U-Cd was log normally distributed.
citrate (1) all three classes included (never smoked, past- and current-smoker). Note, three samples excluded. citrate (2) current-smokers additionally excluded.
citrate (3) past- and current-smokers additionally excluded. ANOVA, analysis of variance; 3-HV, 3-hydroxyisovalerate; DMG, dimethylglycine; 4-DEA, 4-
deoxyerythronic acid; PLS, partial least squares; PLS-DA, partial least squares - discriminant analysis; U-Cd, urinary cadmium.
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smoked (P < 0.01, Mann-Whitney test). There was also a
clear negative trend in citrate levels with smoking status
(Spearman’s r = -0.225, P < 0.01), such that ex-smokers
had intermediate levels of citrate on average compared to
the other two groups (Figure 3A). This suggests that
smoking could have induced a long-term change in
citrate metabolism or transport, possibly reflecting an
effect on mitochondria, which was manifested in
decreased urinary citrate levels.
Association of heavy metal exposure and oxidative stress
Alterations in citrate levels could imply changes in the
consumption of citrate via the Krebs cycle in the mito-
chondrion. A perturbation to oxidative metabolism
would be expected to lead to a change in ROS production
and accompanying oxidative stress. Cd has been shown
to increase ROS production in vivo [31,44] and indirectly
damages DNA in vitro via oxidation by hydrogen perox-
ide production [45]. We attempted to define the associa-
tion of heavy metal exposure (using U-Cd as an
indicator) and the potential for oxidative DNA damage
by measuring U-8-oxodG, which is widely used as a bio-
marker of oxidative stress [46,47]. We measured U-8-
oxodG in a subset of 40 individuals (the upper and lower
15% of volunteers according to U-Cd concentration
(Figure 3B)). The mean U-Cd concentration in the lower
group was 0.115 ± 0.006 (nmol/mmol creatinine ± stan-
dard error of the mean (SEM)) and 0.766 ± 0.052 in the
higher group. There was a significant (P < 0.05, Mann-
Whitney test) increase in U-8-oxodG concentration
(median ± SD) in the individuals in the upper 15th per-
centile group (1.77 ± 0.82 pmol/mmol creatinine), com-
pared to those in the lower group (1.39 ± 0.45 pmol/
mmol creatinine). This suggests a positive association
between U-8-oxodG and U-Cd, which could be represen-
tative of mitochondrial dysfunction and increased ROS
production, consistent with our hypothesis.
Discussion
Mechanistic evidence of chemical toxicity is vital to
allow accurate risk assessment; in this context, multiple
intermediate biomarkers may serve as combinatorial sig-
natures of early molecular events of toxicity. Metabolic
phenotypes can be used as an information-rich endpoint
in molecular epidemiology and can define the interac-
tions of lifestyle, environment and genes that determine
diseases [10]. We have shown here that metabolic profil-
ing can be successfully applied to a human toxicologi-
cal/molecular epidemiological study, specifically in a
population exposed to Cd pollution derived through
environmental exposure, to define associations between
the metabolome, lifestyle and exposure data, and other
molecular biomarkers of tissue damage.
U-Cd concentration in the majority of individuals liv-
ing at the Avonmouth site was within typical estimated
levels of a normal population (0.1 to 0.6 nmol/mmol
creatinine [16]), and only 25% of individuals had U-Cd
levels above 0.5 nmol/mmol creatinine [37] which is the
lower limit of potential risk of renal damage suggested
by the Scientific Committee on Toxicity, Ecotoxicity and
the Environment [48] (CSTEE). The joint FAO/WHO
expert committee on food additives (JECFA) concluded
that an excess prevalence of tubular renal dysfunction
would not be expected below a U-Cd level of 2.5 nmol/
mmol creatinine [49], considerably higher than the
range of U-Cd concentrations at which we observed
metabolic changes. An NMR-based metabolic profiling
approach could complement exposure assessment as it
0
5
10
15
20
25
C
itr
at
e 
(r
el
at
iv
e 
co
nc
en
tr
at
io
n)
Smoking status
0
1
2
3
4
5
8-
ox
od
G
 (
pm
ol
/m
m
ol
 c
re
at
in
in
e)
Percentile of urinary
Cd concentration
**
*
Bottom 15%Never 
smoked
Top 15%Past
smoker
Current
smoker
A B
Figure 3 The association between (A) relative citrate concentration and smoking status, and (B) U-Cd and U-8-oxodG. (A) Normalized
citrate levels in never, past and current smokers. ** statistically significant difference to ‘never smoked’ group, P < 0.01 (Kruskal-Wallis with Mann-
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details actual biochemical disturbance and could aid the
determination of the mechanism of action of a chemical
toxicant and the etiology of associated disease.
We identified a previously unreported association of
urinary citrate to both Cd exposure and smoking. Sur-
prisingly, citrate was positively correlated with U-Cd
and negatively with smoking status, despite smoking
being an important source of cadmium exposure. The
increase in urinary citrate levels associated with U-Cd
may result from Cd-induced tubule toxicity that affects
citrate handling in the kidney [50], although we did not
observe a direct association between citrate levels and
tubular dysfunction (as represented by U-NAG levels).
Smoking may reduce urinary citrate levels due to
reduced capacity for oxidative metabolism in mitochon-
dria. Chronic smoking is associated with a decrease of
complex IV and III activity in the lymphocyte mitochon-
drial electron transfer chain, which returns to normal
after cessation of smoking [51,52]. There was also a
positive association between U-Cd and U-8-oxodG,
which is indicative of increased systemic oxidative stress
and may also result from mitochondrial dysfunction.
Past smokers also had intermediate urinary citrate levels
relative to current smokers and those who had never
smoked. This observation suggests that it may be possi-
ble to monitor biological effects of exposure in indivi-
duals who are no longer exposed to the causative agent,
whether they be irreversible or slow to return to a ‘nor-
mal’ metabolic phenotype.
Using a non-targeted approach 3-HV was found to be
negatively correlated to U-Cd, age and sex, and DMG
negatively correlated to U-Cd and sex. However, after
allowing for confounding factors it was not conclusively
shown that these two metabolites were associated with
U-Cd, possibly due to the limitation of sample numbers.
Despite this, correspondence between our observations
and other studies of the biochemical effects of Cd sug-
gest that these metabolic changes may still be related to
the underlying mechanisms of Cd toxicity. Cd inhibits
oxidoreductases involved in vitamin D metabolism [53]
and 3-HV is a product of the L-leucine mitochondrial
catabolic pathway which also involves this class of
enzymes. One hypothesis is that reduction in urinary 3-
HV could be occurring in parallel to direct mitochon-
drial damage [31,54]. Another of the six metabolites
identified as correlated to U-Cd, 4-DEA, is also involved
in amino acid catabolism: it is a breakdown product of
threonine. Threonine deaminase converts threonine to
alpha-ketobutyrate, a precursor of isoleucine, and this is
further modified by reductases to 4-deoxyerythronic
acid and its diastereoisomer 4-deoxythreonic acid [55]
(also observed in our study but not correlated to U-Cd).
Our study had several limitations: clearly our observa-
tions need to be replicated in other larger cohorts and
we did not have available repeated or alternative biologi-
cal specimens from the study participants. Metabolite
measurements in blood plasma for instance would pro-
vide clarification as to whether the observed associations
were systemic in origin or likely to reflect mainly renal
effects. A detailed analysis of the contribution of diet
and activity to specific metabolite variation was also not
possible. These issues are currently being examined in
follow-up studies (for example, http://www.envirogen-
omarkers.net). In particular it will be important to eval-
uate the additional prognostic value of metabolomic
measurements compared to established clinical pathol-
ogy data and exposure assessment if the metabolites
observed here associated with Cd burden are to be con-
sidered as valuable biomarkers in the future.
Conclusions
Using an NMR-based approach, we have demonstrated
the capacity, in principle, of metabolic profiling to char-
acterize the metabolic consequences of exposure to
environmental toxicants, such as Cd and tobacco
smoke, in a human population. We conclude that meta-
bolic profiling has the potential to identify novel bio-
markers and molecular signatures of the effects of
exposure to many environmental toxicants, and thus
improve risk assessment models, ultimately guiding
intervention to prevent disease progression. As such,
metabolic profiling represents a vital element in future
initiatives to define the human exposome. In the longer
term, the methods employed in the present Cd exposure
study could be used on a broad scale for baseline sur-
veys in health impact assessments for development pro-
jects, going on to play a central role in monitoring
populations living near point sources of pollution such
as industrial sites.
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